Перегляд вихідного коду сторінки Ever Utilizing A MAPK inhibitor You Were Proud Of?

In 2011 Lafum et al., [21] studied UK General Practitioner Research Database (UK-GPRD) for costs of three anti-glaucoma medications, one of them was LT. The study revealed that each patient on LT spent about ? 203.64 per year on LT medication. Patients in our setup spent only about Rs. 3876/year, albeit, 8.6% of per capita/annum income of the family, on their LT medication. Though spending on medications in patients of UK cannot be compared with current spending by our patients, it only indicates relatively less financial burden of drugs on our patients. Many patients coming to government  hospitals often could not sustain this expenditure. The daily cost of glaucoma medications was calculated in China [22] was also higher than from our study. Overall, despite having lower costs of glaucoma medications compared to developed countries, we observed, patients in our set up are [http://www.selleckchem.com/pharmacological_MAPK.html selleck products] reluctant to adhere to medications. Current study provides basic costs (cost of drugs and cost travel) incurred by the patients in government hospitals, which was devoid of consultation fees for doctors, diagnostic and monitoring charges etc. since the infrastructure for diagnosing and monitoring of  POAG are not widely available in India, especially in primary and secondary levels of health care systems, the cost of the treatment is expected to be same or higher, especially when POAG is treated in private hospitals. Further studies are needed to focus on cost-effectiveness by taking more objective parameters using perimeter, monitoring  of POAG progression using fundus camera, which can provide observable changes in POAG, over long period. Because of lack of data on drug loss during drug administration we assumed it to be as one drop/day. But with the improvements in dropper tips in recent years, the drug loss during administration may be minimal in future studies. With drugs cost is expected to come down in coming years [23] in addition to improvements in drug delivery methods, the glaucoma pharmacotherapy is expected to be more cost effective in future. The cost of drug treatment in India is cheaper unlike in developed countries like UK [24], Australia [25]& USA [26]. Limitations The current study has several limitations. We assumed that patients were compliant to medications and did not measure the compliance directly by any objective methods. Nevertheless, we tried our best to find out the compliance by asking indirect questions regarding drug usage. We also assumed that amount of drug loss during administration as one drop per day in our set up. While calculating for costs for transport, we only considered charges incurred by patients. We did not include additional costs of attender, if there was any. We hardly observed any outsider patient coming alone.